2021 business outlook: Revenues are expected to be $16.4 – $16.8 billion (2020 actual results include ~$240 million in revenues from generic products in Japan divested on February 1, 2021, along with a manufacturing site) Non-GAAP EPS is expected to be $2.50 – $2.70 Free cash flow is expected to be $2.0 – $2.3 billion “In 2020, Teva continued to provide essential medicines to millions of patients around the world every day, and despite the COVID-19 pandemic challenges, we saw minimal impact on our supply chain, R&D programs and product launches. Following a strong fourth quarter performance, we have met all components of our 2020 financial guidance,” said Mr. Kåre Schultz, Teva’s President and CEO.